SEC Filings

424B5
AVEXIS, INC. filed this Form 424B5 on 06/19/2017
Entire Document
 

Table of Contents

 


The Offering

Common stock offered by us

           shares.

Common stock to be outstanding after this offering

 

         shares.

Option to purchase additional shares

 

The underwriters have a 30-day option to purchase a maximum of         additional shares of common stock from us.

Use of Proceeds

 

We estimate that the net proceeds to us from this offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, will be $187.3 million, or $215.5 million if the underwriters exercise in full their option to purchase additional shares.

 

We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund our research and manufacturing activities, our planned clinical trials of AVXS-101 in SMA, including our U.S. and E.U. pivotal trials in SMA Type 1 and our Phase 1/2a trial in SMA Type 2, our preclinical studies and Phase 1 clinical trials of our programs in Rett syndrome and ALS, and for general corporate purposes and working capital. See "Use of Proceeds" on page S-13.

Risk Factors

 

See the "Risk Factors" sections of this prospectus supplement and the documents incorporated by reference herein for a discussion of factors you should consider carefully before deciding to invest in our common stock.

The NASDAQ Global Select Market symbol

 

"AVXS"



          The number of shares of our common stock to be outstanding after this offering is based on 27,743,174 shares of our common stock outstanding as of March 31, 2017. This number excludes:

    2,734,141 shares of common stock issuable upon exercise of outstanding stock options as of March 31, 2017, at a weighted-average exercise price of $25.40 per share;

    106,232 shares of common stock issuable upon the settlement of outstanding restricted stock units as of March 31, 2017;

    305,775 shares of common stock issuable upon the exercise of outstanding warrants as of March 31, 2017, at a weighted-average exercise price of $2.57 per share; and

    up to a maximum of 2,607,080 shares of common stock reserved for future issuance under our 2016 Equity Incentive Plan, or the 2016 Plan, as of March 31, 2017, as well as any automatic increase in the number of shares of common stock reserved for future issuance under the 2016 Plan.

          Except as otherwise indicated, all information in this prospectus supplement reflects and assumes:

    no exercise of outstanding options, restricted stock units or warrants after March 31, 2017; and

    no exercise by the underwriters of their option to purchase additional shares of our common stock.

S-5



© AveXis, Inc. All Rights Reserved.